K.J. Harrison & Partners Inc Acquires 10,967 Shares of CVS Health Corp (CVS)

Share on StockTwits

K.J. Harrison & Partners Inc raised its holdings in shares of CVS Health Corp (NYSE:CVS) by 140.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 18,775 shares of the pharmacy operator’s stock after acquiring an additional 10,967 shares during the quarter. K.J. Harrison & Partners Inc’s holdings in CVS Health were worth $1,478,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CVS. Camarda Financial Advisors LLC purchased a new stake in shares of CVS Health during the second quarter valued at approximately $102,000. Kiley Juergens Wealth Management LLC purchased a new stake in shares of CVS Health during the second quarter valued at approximately $103,000. Legacy Advisors LLC raised its stake in shares of CVS Health by 7,100.0% during the second quarter. Legacy Advisors LLC now owns 1,800 shares of the pharmacy operator’s stock valued at $116,000 after purchasing an additional 1,775 shares during the period. Squar Milner Financial Services LLC purchased a new stake in shares of CVS Health during the second quarter valued at approximately $122,000. Finally, Canton Hathaway LLC purchased a new stake in shares of CVS Health during the third quarter valued at approximately $126,000. 82.62% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NYSE:CVS opened at $72.39 on Thursday. The company has a debt-to-equity ratio of 1.73, a current ratio of 2.34 and a quick ratio of 1.87. The firm has a market capitalization of $73.70 billion, a P/E ratio of 12.27, a P/E/G ratio of 0.97 and a beta of 1.02. CVS Health Corp has a 12-month low of $60.14 and a 12-month high of $83.88.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, August 8th. The pharmacy operator reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.08. CVS Health had a net margin of 1.61% and a return on equity of 18.25%. The business had revenue of $46.71 billion during the quarter, compared to analyst estimates of $46.34 billion. During the same quarter in the previous year, the firm earned $1.33 earnings per share. The business’s revenue was up 2.2% compared to the same quarter last year. Equities research analysts predict that CVS Health Corp will post 7.01 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 1st. Shareholders of record on Wednesday, October 24th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, October 23rd. This represents a $2.00 annualized dividend and a yield of 2.76%. CVS Health’s payout ratio is 33.90%.

In other CVS Health news, EVP Eva C. Boratto sold 13,311 shares of the business’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.16, for a total transaction of $1,027,076.76. Following the completion of the sale, the executive vice president now owns 55,162 shares in the company, valued at $4,256,299.92. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Lisa Bisaccia sold 21,534 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $80.00, for a total transaction of $1,722,720.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 43,409 shares of company stock valued at $3,392,097. 0.53% of the stock is owned by insiders.

CVS has been the topic of a number of analyst reports. Royal Bank of Canada reiterated a “buy” rating and set a $90.00 price objective on shares of CVS Health in a research note on Wednesday, August 8th. Citigroup restated a “buy” rating and issued a $81.00 price target on shares of CVS Health in a research note on Monday, July 9th. Bank of America lifted their price target on shares of CVS Health from $86.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. Tigress Financial restated a “buy” rating on shares of CVS Health in a research note on Friday, October 26th. Finally, ValuEngine upgraded shares of CVS Health from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, five have assigned a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $86.18.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Recommended Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply